ArticleMolecular diversity2026
Targeting cathepsin B activity by natural inhibitors: a structural dynamics and network pharmacology approach for amyloid-beta dysregulation in Alzheimer's disease.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is characterized by progressive cognitive decline and pathological accumulation of amyloid-beta (Aβ). Cathepsin B (CatB) has been implicated in both Aβ degradation and amyloidogenic APP processing; this compartment-dependent dualism makes CatB a complex but intriguing target, where selective inhibition of pathogenic activities (rather than global inhibition) is likely required for therapeutic benefit. In this research, we used an integrated computational pipeline to discover effective CatB inhibitors from a natural product-like compound library. A tiered virtual screening methodology (HTVS, SP, XP) was complemented by MMGBSA rescoring to yield F3382-3724, F6617-5583, and F6617-3074 as strong candidates. DFT B3LYP-D3/6-31G optimization confirmed F6617-5583 to possess the most stable electronic structure, followed by F3382-3724. Molecular dynamics simulations of 500 ns indicated that all complexes exhibited protein RMSD values below 2.0 Å, with F6617-5583 achieving conformational stability earlier, showing ligand RMSD values between 3.0-3.5 Å similar to the reference inhibitor. MMGBSA calculations identified F6617-5583 as the most potent binder (ΔG_bind = - 74.92 ± 3.10 kcal/mol), primarily stabilized by van der Waals and lipophilic interactions. Consistent interactions involving catalytic residues such as Trp30 and Trp221 facilitated stable ligand retention. PCA and Free Energy Landscape analyses further supported the localization of F6617-5583 in a low-energy conformational pocket indicative of strong and specific binding. A compound-gene interaction network constructed using NetworkX and Matplotlib revealed distinct connectivity patterns, providing insights into potential polypharmacological effects. Collectively, these results establish F6617-5583 as the lead CatB inhibitor, while F3382-3724 remains a promising secondary candidate for further optimization in Alzheimer's disease therapeutics.
Indexed as
Identifiers
41160337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.